STAGE 4 PROSTATE
CANCER TREATMENT
Stage 4 prostate cancer has developed a treatment model closer to chronic disease management than any other metastatic solid tumour. Decisions made at the hormone-sensitive stage have lasting consequences for every subsequent treatment line.
Stage 4 Prostate Cancer Treatment by Disease State
| Disease State | Treatment | Key Notes |
|---|---|---|
| mHSPC: ADT plus ARPI | Abiraterone, enzalutamide, apalutamide, or darolutamide plus ADT | All four demonstrated OS improvement over ADT alone in Phase III trials. Standard intensification approach. |
| mHSPC: Triplet therapy (high-volume) | ADT plus docetaxel plus darolutamide (ARASENS) or abiraterone (PEACE-1) | Additional benefit shown in high-volume metastatic disease in fit patients. |
| mCRPC: ARPI | Enzalutamide, abiraterone, apalutamide, darolutamide | For ARPI-naive patients. Sequencing depends on what was used at hormone-sensitive stage. |
| mCRPC: PARP inhibitors | Olaparib, rucaparib (BRCA1/2); niraparib (HRR mutations) | Approximately 20-25% of mCRPC carry HRR mutations. Require somatic or germline molecular testing. |
| mCRPC: 177Lu-PSMA-617 | Lutetium PSMA radioligand therapy | VISION trial: improved OS and rPFS. Requires PSMA-positive imaging, prior ARPI and taxane. |
| mCRPC: Chemotherapy | Docetaxel first; cabazitaxel second chemotherapy line | Docetaxel remains a standard option at CRPC if not used at hormone-sensitive stage. |
| Bone metastases (no visceral) | Radium-223 | Extends OS in symptomatic bone metastases without visceral disease. |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Stage 4 Prostate Cancer Treatment?
CancerFax reviews your disease state, molecular profile, and prior treatment history to identify which stage 4 prostate cancer treatment options are most relevant for your situation.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.